Consort Medical plc (LON:CSRT) insider Paul Hayes purchased 14 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were purchased at an average price of GBX 1,088 ($14.30) per share, for a total transaction of £152.32 ($200.26).

Paul Hayes also recently made the following trade(s):

  • On Thursday, September 7th, Paul Hayes purchased 14 shares of Consort Medical plc stock. The shares were purchased at an average price of GBX 1,088 ($14.30) per share, for a total transaction of £152.32 ($200.26).
  • On Monday, August 7th, Paul Hayes purchased 13 shares of Consort Medical plc stock. The shares were purchased at an average price of GBX 1,100 ($14.46) per share, for a total transaction of £143 ($188.01).

Shares of Consort Medical plc (LON CSRT) traded down 0.65% during mid-day trading on Wednesday, hitting GBX 1068.00. The stock had a trading volume of 169 shares. The stock’s market cap is GBX 522.39 million. Consort Medical plc has a 12-month low of GBX 960.00 and a 12-month high of GBX 1,180.00. The company’s 50 day moving average price is GBX 1,089.22 and its 200 day moving average price is GBX 1,055.88.

TRADEMARK VIOLATION NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/insider-buying-consort-medical-plc-csrt-insider-buys-14-shares-of-stock.html.

A number of research analysts have commented on CSRT shares. Panmure Gordon restated a “buy” rating and set a GBX 1,145 ($15.05) price target on shares of Consort Medical plc in a research note on Thursday, June 15th. Investec restated a “buy” rating and set a GBX 1,165 ($15.32) price target on shares of Consort Medical plc in a research note on Thursday, June 15th. Stifel Nicolaus restated a “hold” rating and set a GBX 1,100 ($14.46) price target on shares of Consort Medical plc in a research note on Thursday, June 15th. Numis Securities Ltd restated a “hold” rating and set a GBX 1,084 ($14.25) price target on shares of Consort Medical plc in a research note on Thursday, June 15th. Finally, Shore Capital restated a “buy” rating on shares of Consort Medical plc in a research note on Thursday, June 15th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Consort Medical plc currently has an average rating of “Buy” and a consensus price target of GBX 1,153.17 ($15.16).

About Consort Medical plc

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.